*By Madison Alworth*
Crypto start-up StreetCred wants everyday New Yorkers to map their city, and the company is paying them in Bitcoin to get the job done.
"You can earn points for going around the city and adding and taking photos of any place that you go that's of interest to other people," CEO Randy Meech said Monday in an interview on Cheddar.
StreetCred's app, MapNYC, isn't the first mapping product out there, of course. Google's version similarly uses crowd-sourced information to beef up its offering. But Meech sees a key downfall to that option.
"One of the problems is, it's very restrictive and very expensive for other companies to use," he said. "That's really our mission. We are trying to make this data very accessible, very open, basically, for others to do anything that they want with it."
Meech hopes to address those concerns by running his app on a more decentralized blockchain.
"What we're looking for is for communities to be able to create data and be compensated for that, or to share it with companies who need the data," said Meech.
Bitcoin is the currency of choice, since it's currently the one most visible to the general public and therefore has the potential to attract more contributors. But StreetCred does have bigger ambitions.
"We are a crypto company so we will likely be having our own token at some point," Meech said. "One of things we wanted to test, before we get to that point, is will people do this for crypto?"
Creating a game out of it may help. Every time a user posts a location, he or she gets a point, and prizes will be distributed among those who post the most. As of this week, there are eight Bitcoins up for grabs in the app's contest; the top prize equals one Bitcoin, or approximately [$6,200] (https://www.coindesk.com/price/).
StreetCred is focusing on its hometown of NYC to start, but Meech said he plans to expand beyond his test city. MapNYC launches on September 24 and will be available for both iOS and Android.
For full interview [click here](https://cheddar.com/videos/mapping-nyc-for-bitcoin).
Paramount Global is set to absorb Showtime into Paramount+, creating a single streaming option to compete with the likes of Netflix and Warner Bros. Discovery’s Max. The company also plans to raise the monthly price from $9.99 to $11.99 per month after the integration.
Debt ceiling talks are underway in Washington, DC ahead of a default deadline. Michael Rosen, chief investment officer with Angeles Investments, joined Cheddar News to explain how a potential default could affect investment portfolios, among other items, for Americans.
Australia's government announced regulations for buy now, pay later services, which will be labeled as consumer credit products, which puts them under the country's Securities and Investments Commission's watch.
Walmart is reportedly teaming up with pet telehealth provider Pawp, giving subscribers unlimited access to vet services via video and text, starting on Tuesday.
Cheddar News checks in to see what's on The Day Ahead, which will include earnings from Lowe's, Dick's Sporting Goods, BJ's and AutoZone along with new home sales data. In addition, Microsoft's Build 2023 Developer Conference is slated to kick off for software engineers and web developers.
Amazon will use a new feature in its palm-scanning system to verify one's age to purchase alcohol.
Venmo will soon have accounts for teenagers ages 13-17 but they will have to follow a set of rules, with parents or guardians opening accounts on their behalf under their own accounts.
Rory Harvey, General Motors' incoming North American president, joined Cheddar News to discuss GM's foray into the rapidly-changing electric vehicle market along with what lies ahead. "It's a very dynamic time in the automotive industry," he said. "If you look to the transformation across the EVs, it's happening and it's happening at a pace."
Tesla trimmed prices by offering discounts of around $1,300 for its Model 3 vehicles, continuing price adjustments across its fleet since January.
A new oral weight-loss drug from Pfizer could be more effective than the popular Ozempic injection, based on clinical trial results.
